See Asa at Microbiome & Probiotic R&D & Business Collaboration Forum - La Jolla, California 10/13/2025
November 24, 2021 By: Asa Waldstein

“Clinically proven” statements are high risk

Takeaway -

Use caution with “clinically proven” or “clinically studied” statements

Implying “Clinically Proven” or even “Clinically Studied” is high risk. This is a trend to watch out for. We are seeing references to “clinically proven” types of claims showing up not just in warning letters but also in class action lawsuits and NAD complaints.

The highest burden of proof is “clinically proven”. This is rare in dietary supplements and should be used only if proper substantiation exists.

The next highest burden of proof is “clinically studied”. This requires the formula to be studied with scientifically significant methods. Bench or pilot tests may not qualify as “clinically studied”. This can be difficult when using branded ingredients that may have been researched but perhaps do not meet a “clinically studied” standard. Most branded ingredients have sound research but some may not. It is important to conduct a proper review before using ingredient science on face value.

A “clinically studied ingredient” is different than a “clinically studied product”. There are many factors including serving size, formulation, and delivery form that play a role in this. We talk about what defines clinically proven here.

If accurate, I prefer using descriptions such as “thoughtfully formulated with well-researched ingredients”.

What are your thoughts?

Disclaimer: The educational information provided here is for informational purposes only. Contact an attorney for specific legal advice. Rule #1 in compliance is to ensure marketing is truthful and not misleading.

Written by

Asa Waldstein
Asa Waldstein
Asa Waldstein is a 24-year veteran of the dietary supplement industry, with experience spanning manufacturing, marketing, and regulatory compliance. He is the principal of Apex Compliance, a software company dedicated to streamlining regulatory marketing compliance for the dietary supplement and natural products sectors. Asa also leads Supplement Advisory Group, a boutique consultancy focused on marketing risk analysis, labeling, and practical compliance strategies for websites and social media. Asa has helped oversee three FDA GMP inspections with no 483s and was honored with the 2023 AHPA Herbal Hero Award and the 2024 What's Up Supps Policy and Change Agent Award. He currently serves as Chair of the American Herbal Products Association’s (AHPA) Cannabis Committee, helping shape policy and industry best practices